Biotech | December 08, 2025
Freenome strikes SPAC deal to go public in 2026
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
MRI is particularly valuable in pediatric care due to its non-invasive nature
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
The company is excluding data from the affected sites to maintain the study's integrity
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Subscribe To Our Newsletter & Stay Updated
